- A small randomized controlled trial (RCT) of intra-articular injection of culture-expanded mesenchymal stem cells (MSCs) with or without platelet-rich plasma (PRP) finds improvement in most pain, symptoms, and daily living outcomes, but not in range of motion (ROM), in patients with knee osteoarthritis (KOA).
Why this matters
- This RCT is among the first investigations of MSCs±PRP.
- Double-blind RCT of 47 patients with KOA, most with Kellgren-Lawrence grade III (41.1%).
- Patients were randomly assigned to 1 of 3 groups:
- Autologous bone marrow-derived culture-expanded MSCs.
- Autologous bone marrow-derived culture-expanded MSCs+PRP.
- Main outcomes were improvement in 5 domains and global Knee Injury and Osteoarthritis Outcome Score (KOOS) and ROM.
- Funding: None.
- At 1 year vs baseline:
- No improvement in ROM in any of the groups.
- The control group only improved in 2 KOOS domains: pain (P=.029) and daily living function (P=.030).
- The MSC group improved in 5 KOOS domains: symptoms (P=.010), pain (P=.008), daily living function (P=.003), sports/recreation (P=.001), QoL (P=.009); plus global KOOS score (P=.002).
- The MSC+PRP group improved in 4 KOOS domains: symptoms (P=.025), pain (P<.001 daily living function sports plus global koos score>
- All groups showed reduction in IL-10 levels.
- Small sample sizes.